C3 nephritic factor associated with C3 glomerulopathy in children

被引:26
作者
Nicolas, Camille [1 ]
Vuiblet, Vincent [2 ]
Baudouin, Veronique [4 ]
Macher, Marie-Alice [4 ]
Vrillon, Isabele [5 ]
Biebuyck-Gouge, Nathalie [6 ]
Dehennault, Maud [7 ]
Gie, Sophie [8 ]
Morin, Denis [9 ]
Nivet, Hubert [10 ]
Nobili, Francois [11 ]
Ulinski, Tim [12 ]
Ranchin, Bruno [13 ]
Marinozzi, Maria Chiarra [14 ]
Ngo, Stephanie [3 ]
Fremeaux-Bacchi, Veronique [3 ,16 ]
Pietrement, Christine [1 ,15 ]
机构
[1] CHU Reims, Dept Pediat, Nephrol Unit, Reims, France
[2] CHU Reims, Dept Pathol, Dept Nephrol, Reims, France
[3] Hop Europeen Georges Pompidou, AP HP, Dept Immunol, Paris, France
[4] Hop Robert Debre, AP HP, Dept Pediat Nephrol, F-75019 Paris, France
[5] CHU Nancy, Dept Pediat, Nephrol Unit, Nancy, France
[6] Hop Necker Enfants Malad, AP HP, Dept Pediat Nephrol, Paris, France
[7] CHRU Lille Jeanne de Flandre, Dept Pediat, Nephrol Unit, Lille, France
[8] CHU Rennes, Dept Pediat, Nephrol Unit, Rennes, France
[9] CHU Montpellier, Dept Pediat, Nephrol Unit, Montpellier, France
[10] CHU Tours, Dept Pediat, Nephrol Unit, Tours, France
[11] CHU Besancon, Dept Pediat, Nephrol Unit, F-25030 Besancon, France
[12] Hop Trousseau, AP HP, Dept Pediat Nephrol, F-75571 Paris, France
[13] Hop Femme Mere Enfant, Dept Pediat Nephrol, Bron, France
[14] CRC Paris, INSERM, Umrs872, Paris, France
[15] CHU Reims, F-51092 Reims, France
[16] Hop Europeen Georges Pompidou, Serv Immunol Biol, F-75908 Paris 15, France
关键词
Complement alternative pathway; C3; glomerulonephritis; Dense deposit disease; Membranoproliferative glomerulonephritis; glomerulopathy; DENSE-DEPOSIT DISEASE; CHILDHOOD MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; HEMOLYTIC-UREMIC SYNDROME; MESANGIOCAPILLARY GLOMERULONEPHRITIS; ALTERNATIVE PATHWAY; COMPLEMENT ABNORMALITIES; MYCOPHENOLATE-MOFETIL; CLINICAL-FEATURES; PROTEIN; CLASSIFICATION;
D O I
10.1007/s00467-013-2605-6
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
C3 glomerulopathy (C3G) is characterized by predominant C3 deposits in glomeruli and dysregulation of the alternative pathway of complement. Half of C3G patients have a C3 nephritic factor (C3NeF). C3G incorporated entities with a range of features on microscopy including dense deposit diseases (DDD) and C3 glomerulonephritis (C3GN). The aim of this work was to study children cases of C3G associated with C3NeF. We reviewed 18 cases of C3G with a childhood onset associated with C3NeF without identified mutations in CFH, CFI, and MCP genes. Clinical histories started with recurrent hematuria for seven patients, nephrotic syndrome for four, acute post-infectious glomerulonephritis for three and acute renal failure for four. Twelve patients had a low C3 at first investigation. Kidney biopsy showed ten C3GN and eight DDD. Twenty-three percent of the patients tested presented elevated sC5b9. Seven patients relapsed 3 to 6 years after the onset. At the end of follow-up, two patients were under dialysis, 11 had a persistent proteinuria, five had none; four patients did not follow any treatment. Steroids were first used in 80 % of cases. C3NeF associated C3G has a heterogeneous presentation and outcome. Anti-proteinuric agents may control the disease during follow-up, even after nephrotic syndrome at the onset. The efficiency of immunosuppressive therapy remains questionable.
引用
收藏
页码:85 / 94
页数:10
相关论文
共 43 条
[1]   Membranoproliferative glomerulonephritis [J].
Alchi, Bassam ;
Jayne, David .
PEDIATRIC NEPHROLOGY, 2010, 25 (08) :1409-1418
[2]   Membranoproliferative glomerulonephritis type II (dense deposit disease):: An update [J].
Appel, GB ;
Cook, HT ;
Hageman, G ;
Jennette, JC ;
Kashgarian, M ;
Kirschfink, M ;
Lambris, JD ;
Lanning, L ;
Lutz, HU ;
Meri, S ;
Rose, NR ;
Salant, DJ ;
Sethi, S ;
Smith, RJH ;
Smoyer, W ;
Tully, HF ;
Tully, SP ;
Walker, P ;
Welsh, M ;
Würzner, R ;
Zipfel, PF .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (05) :1392-1403
[3]  
Bahat E, 2007, J NEPHROL, V20, P234
[4]   MESANGIOCAPILLARY GLOMERULONEPHRITIS TYPE-II (DENSE-DEPOSIT DISEASE) - CLINICAL-FEATURES OF PROGRESSIVE DISEASE [J].
BENNETT, WM ;
FASSETT, RG ;
WALKER, RG ;
FAIRLEY, KF ;
DAPICE, AJF ;
KINCAIDSMITH, P .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1989, 13 (06) :469-476
[5]   IDIOPATHIC MESANGIOCAPILLARY GLOMERULONEPHRITIS - COMPARISON OF TYPE-I AND TYPE-II IN CHILDREN AND ADULTS AND LONG-TERM PROGNOSIS [J].
CAMERON, JS ;
TURNER, DR ;
HEATON, J ;
WILLIAMS, DG ;
OGG, CS ;
CHANTLER, C ;
HAYCOCK, GB ;
HICKS, J .
AMERICAN JOURNAL OF MEDICINE, 1983, 74 (02) :175-192
[6]   TREATMENT OF MESANGIOCAPILLARY GLOMERULONEPHRITIS IN CHILDREN WITH COMBINED IMMUNOSUPPRESSION AND ANTICOAGULATION [J].
CHAPMAN, SJ ;
CAMERON, JS ;
CHANTLER, C ;
TURNER, D .
ARCHIVES OF DISEASE IN CHILDHOOD, 1980, 55 (06) :446-451
[7]   Mycophenolate mofetil treatment for primary glomerular diseases [J].
Choi, MJ ;
Eustace, JA ;
Gimenez, LF ;
Atta, MG ;
Scheel, PJ ;
Sothinathan, R ;
Briggs, WA .
KIDNEY INTERNATIONAL, 2002, 61 (03) :1098-1114
[8]   C3 glomerulopathy: what's in a name? [J].
D'Agati, Vivette D. ;
Bomback, Andrew S. .
KIDNEY INTERNATIONAL, 2012, 82 (04) :379-381
[9]  
DAMICO G, 1992, J AM SOC NEPHROL, V2, pS159
[10]  
Emre Sevinc, 1995, Acta Paediatrica Japonica, V37, P626